|
|
|
|
| LEADER |
03810nam a2200841 4500 |
| 001 |
ocn811850420 |
| 003 |
OCoLC |
| 005 |
20170124070554.1 |
| 006 |
m o d |
| 007 |
cr ||||||||||| |
| 008 |
121002s2013 nju ob 001 0 eng |
| 010 |
|
|
|a 2012040270
|
| 040 |
|
|
|a DLC
|b eng
|e pn
|c DLC
|d YDX
|d DG1
|d N$T
|d YDXCP
|d E7B
|d CDX
|d IDEBK
|d COO
|d NOC
|d OCLCF
|d CCO
|d NLGGC
|d RECBK
|d EBLCP
|d OCLCQ
|d OCLCO
|d D6H
|d LOA
|d GrThAP
|
| 019 |
|
|
|a 828793860
|a 961568624
|a 962707379
|a 966257693
|
| 020 |
|
|
|a 9781118354582
|q (epub)
|
| 020 |
|
|
|a 1118354583
|q (epub)
|
| 020 |
|
|
|a 9781118354575
|q (pdf)
|
| 020 |
|
|
|a 1118354575
|q (pdf)
|
| 020 |
|
|
|a 9781118354568
|q (mobi)
|
| 020 |
|
|
|a 1118354567
|q (mobi)
|
| 020 |
|
|
|a 9781118354599
|q (electronic bk.)
|
| 020 |
|
|
|a 1118354591
|q (electronic bk.)
|
| 020 |
|
|
|a 9781299241954
|q (MyiLibrary)
|
| 020 |
|
|
|a 1299241956
|q (MyiLibrary)
|
| 020 |
|
|
|z 9780470646274
|q (cloth)
|
| 020 |
|
|
|z 0470646276
|q (cloth)
|
| 029 |
1 |
|
|a AU@
|b 000050086446
|
| 029 |
1 |
|
|a CHBIS
|b 009914530
|
| 029 |
1 |
|
|a CHVBK
|b 175204659
|
| 029 |
1 |
|
|a DKDLA
|b 820120-katalog:000655910
|
| 029 |
1 |
|
|a NLGGC
|b 356864928
|
| 029 |
1 |
|
|a NZ1
|b 15340367
|
| 029 |
1 |
|
|a NZ1
|b 15905471
|
| 029 |
1 |
|
|a DEBBG
|b BV043395079
|
| 035 |
|
|
|a (OCoLC)811850420
|z (OCoLC)828793860
|z (OCoLC)961568624
|z (OCoLC)962707379
|z (OCoLC)966257693
|
| 042 |
|
|
|a pcc
|
| 050 |
0 |
0 |
|a RM301.4
|b .F87 2013
|
| 060 |
1 |
0 |
|a QU 450
|
| 072 |
|
7 |
|a MED
|x 071000
|2 bisacsh
|
| 082 |
0 |
0 |
|a 615.7
|2 23
|
| 049 |
|
|
|a MAIN
|
| 245 |
0 |
0 |
|a Fusion protein technologies for biopharmaceuticals :
|b applications and challenges /
|c edited by Stefan R. Schmidt.
|
| 264 |
|
1 |
|a Hoboken, New Jersey :
|b John Wiley & Sons,
|c [2013]
|
| 264 |
|
4 |
|c ©2013
|
| 300 |
|
|
|a 1 online resource.
|
| 336 |
|
|
|a text
|b txt
|2 rdacontent
|
| 337 |
|
|
|a computer
|b c
|2 rdamedia
|
| 338 |
|
|
|a online resource
|b cr
|2 rdacarrier
|
| 504 |
|
|
|a Includes bibliographical references and index.
|
| 588 |
0 |
|
|a Print version record and CIP data provided by publisher.
|
| 505 |
0 |
|
|a pt. 1. Introduction -- pt. 2. The triple t paradigm : time, toxin, targeting -- pt. 3. Beyond the triple t-paradigm.
|
| 520 |
|
|
|a The state of the art in biopharmaceutical FUSION PROTEIN DESIGN Fusion proteins belong to the most lucrative biotech drugs-with Enbrel® being one of the best-selling biologics worldwide. Enbrel® represents a milestone of modern therapies just as Humulin®, the first therapeutic recombinant protein for human use, approved by the FDA in 1982 and Orthoclone® the first monoclonal antibody reaching the market in 1986. These first generation molecules were soon followed by a plethora of recombinant copies of natural human proteins, and in 1998, the first de novo designed fusion protei.
|
| 650 |
|
0 |
|a Biopharmaceutics.
|
| 650 |
|
0 |
|a Pharmaceutical biotechnology.
|
| 650 |
|
4 |
|a Drug carriers.
|
| 650 |
|
4 |
|a Immunotoxins
|x Therapeutic use.
|
| 650 |
|
4 |
|a Protein engineering.
|
| 650 |
|
4 |
|a Recombinant fusion proteins
|x Therapeutic use.
|
| 650 |
|
7 |
|a MEDICAL
|x Pharmacology.
|2 bisacsh
|
| 650 |
|
7 |
|a Biopharmaceutics.
|2 fast
|0 (OCoLC)fst00832650
|
| 650 |
|
7 |
|a Pharmaceutical biotechnology.
|2 fast
|0 (OCoLC)fst01060106
|
| 650 |
|
2 |
|a Recombinant Fusion Proteins
|x therapeutic use.
|
| 650 |
|
2 |
|a Drug Carriers.
|
| 650 |
|
2 |
|a Immunotoxins
|x pharmacokinetics.
|
| 650 |
|
2 |
|a Immunotoxins
|x therapeutic use.
|
| 650 |
|
2 |
|a Protein Engineering.
|
| 650 |
|
2 |
|a Recombinant Fusion Proteins
|x pharmacokinetics.
|
| 655 |
|
4 |
|a Electronic books.
|
| 655 |
|
7 |
|a Electronic books.
|2 local
|
| 700 |
1 |
|
|a Schmidt, Stefan R.
|
| 776 |
0 |
8 |
|i Print version:
|t Fusion protein technologies for biopharmaceuticals.
|d Hoboken, N.J. : John Wiley & Sons, ©2013
|z 9780470646274
|w (DLC) 2012039440
|
| 856 |
4 |
0 |
|u https://doi.org/10.1002/9781118354599
|z Full Text via HEAL-Link
|
| 994 |
|
|
|a 92
|b DG1
|
